AGENAgenus Inc.

1. Aug 18, 2026On August 12, 2026, Agenus West, LLC (the “Borrower”), a subsidiary of Agenus Inc. (the “Company”), and the Company, as guarantor, entered into a Second Loan Modification Agreement (the “Loan Modification Agreement”) with Ocean 1181 LLC (the “Lender”) relating to the promissory note previously entered into with the …Material agreement entered · Form 8-K
2. Aug 13, 2026On August 10, 2026, the Compensation Committee (the "Committee") of the Board of Directors of Agenus Inc. (the "Company") approved a special, one-time performance-based stock option award to Garo H. Armen, Ph.D., the Company’s Chairman and Chief Executive Officer, under and subject to the Company’s Amended and …Director or officer change · Form 8-K
3. Aug 11, 2026On August 5, 2026, the board of directors (the “Board”) of Agenus Inc., a Delaware corporation (the “Company”), increased the size of the Board from six (6) to seven (7) directors and appointed Marco Tullio Marcucci to fill the resulting vacancy as a Class II director, to serve until the Company’s 2029 annual meeting …Director or officer change · Form 8-K
4. Aug 6, 2026Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer.Earnings release · press release
5. Jul 13, 2026On July 13, 2026, Agenus Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and other accredited investors (each, a “Purchaser” and collectively, the “Purchasers”)Material agreement entered · Form 8-K
6. Jul 6, 2026On June 29, 2026, Agenus Inc. (the “Company”) entered into an Amendment to Notes, Extension of Warrants and Sale of New Warrants (the “Amendment”) with existing noteholders, pursuant to which the Company: • extended the maturity date of $5.09 million of senior subordinated promissory notes previously issued by the …Material agreement entered · Form 8-K
7. May 15, 2026Departure of Principal Accounting Officer On May 12, 2026, Austin Charette, Senior Director, Financial Reporting and Compliance and Principal Accounting Officer of Agenus Inc. (the "Company"), informed the Company he will be resigning effective May 29, 2026.Director or officer change · Form 8-K
8. May 11, 2026Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development.Earnings release · press release
9. Mar 26, 2026On March 24, 2026, the United States District Court for the District of Massachusetts issued a Memorandum and Order in Byron Olsen, Individually and on Behalf of All Others Similarly Situated v.Other event · Form 8-K
10. Mar 16, 2026Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized.Earnings release · press release
11. Jan 16, 2026As previously disclosed, on June 3, 2025, Agenus Inc. (the “Company”) and its wholly-owned subsidiary Agenus West, LLC (“Agenus West” and together with the Company, “Agenus”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Zydus Pharmaceuticals (USA) Inc. (subsequently assigned to Zydilac Bio …Acquisition or disposition completed · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.